Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
The first cardiovascular safety trial of a GLP-1R agonist, demonstrating that lixisenatide does not augment MACE in patients with T2DM who had a recent acute coronary event
The predominance of liraglutide in this study suggests that prescribers prioritize familiarity and established efficacy when selecting GLP-1 receptor agonists
She sees the new pill version as a way to make the medicine more accessible
The most commonly observed adverse events (incidence of 5% and twice that of placebo) were oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation and fecal incontinence
US$ 26.61
US$ 23.81
US$ 20.35
US$ 28.04
US$ 21.06
US$ 25.31
